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To test the feasibility and efficacy of epirubicin and ifosfamide added to first-line chemotherapy with cisplatin and paclitaxel in a
phase II randomised clinical trial. Patients with histologically proven epithelial ovarian cancer were randomly assigned to receive first-
line polychemotherapy with cisplatin/paclitaxel/epirubicin (CEP) or cisplatin/paclitaxel/ifosfamide (CIP) for six cycles every 21 days.
Two hundred and eight patients were randomised between the two treatment arms and the median number of cycles per patient
was six. Toxicity was predominantly haematological with both regimens; however, anaemia, leucopaenia, neutropaenic fever and use
of granulocyte colony-stimulating factors and transfusion were significantly more frequent in the CIP treatment arm. Response rates
were 85% (95% confidence interval (CI) 77–93%) in the CIP arm and 90% (95% CI 84–96%) in the CEP arm; complete response
rates were 48 and 52%. After a median follow-up of 82 months, median overall survival (OS) was 51 and 65 months; 5-year survival
rates were respectively 43 and 50%. In this clinical trial, both regimens showed good efficacy, but toxicity was heavier with the CIP
regimen. Considering that more than 50% of patients were suboptimally debulked after the first surgery, OS seems to be longer than
is commonly reported. This unexpected finding might be a consequence of the close surgical surveillance and aggressive
chemotherapeutic approach.
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Advanced epithelial ovarian cancer treatment is still a challenge for
gynaecologic oncologists. Despite recent improvements in treat-
ment, most ovarian cancer patients will relapse eventually, and
only about one-third are alive after 5 years (Heintz et al, 2006).
Today, cytoreductive surgery followed by six cycles of
carboplatin/paclitaxel is widely accepted as the standard therapy
for advanced ovarian cancer (McGuire et al, 1996; du Bois et al,
1997; Neijt et al, 2000; Piccart et al, 2000). Attempts to improve
long-term survival have involved the addition of a third non-cross-
resistant drug with proven antitumour activity to first-line
chemotherapy .
We report here a large phase II clinical trial that started in 1997
with the primary objective of exploring the effects in terms of
toxicity, response to therapy and survival of the addition of
epirubicin and ifosfamide to the cisplatin/paclitaxel regimen.
Cisplatin was chosen because it was the standard platinum
compound used in ovarian cancer when the trial started. A few
years later, cisplatin was replaced by carboplatin, because it was
better tolerated with an improved quality of life. Indeed two large,
independent phase III trials conducted by AGO and GOG reported
similar efficacy for the two drugs (du Bois et al, 2003; Ozols et al,
2003).
Until recently, epirubicin was considered an option mainly for
the treatment of recurrent or platinum-resistant disease (Ray-
Coquard et al, 2003; Buda et al, 2004), with similar antitumour
activity but fewer side effects than doxorubicin (Maluf and Spriggs,
2002). Doxorubicin had a significant impact on the response rate
and on the long-term overall survival (OS) when added to first-line
chemotherapy with cisplatin (The Ovarian Cancer meta-analysis
project, 1991; Fanning et al, 1992; A’Hern and Gore, 1995).
Epirubicin too has been tested in several phase I/II trials in
combination with paclitaxel and carboplatin at doses of 60 or
75mgm
 2, with promising results, the main toxicity of the
combination being myelosuppression (Hill et al, 1997; Naumann
et al, 1998; du Bois et al, 1999; Gregory et al, 2000; Papadimitriou
et al, 2000; Fleming et al, 2001; Kristensen et al, 2003; Romanini
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set al, 2003). However, two recent randomised clinical trials found
that the addition of epirubicin to standard treatment did not
improve OS or progression-free survival (PFS) (Kristensen et al,
2005; du Bois et al, 2006).
The second drug we decided to study in this trial in addition to
cisplatin and paclitaxel was ifosfamide. Ifosfamide has been
studied in combination with other drugs such as etoposide,
topotecan and vinorelbine for the treatment of recurrent epithelial
ovarian cancer (Gonzalez-Martin et al, 2002; Chiara et al, 2004;
Shaheen et al, 2004). Shortly after the start of this clinical trial, in a
phase I and a phase II trial of cisplatin and paclitaxel combined
with ifosfamide, significant activity against ovarian epithelial
cancer was noted. The regimen was feasible with ifosfamide doses
up to 5gm
 2 (Kosmas et al, 2001; Papadimitriou et al, 2001).
PATIENTS AND METHODS
Patients
Women 18 years of age or older with histologically proven
epithelial ovarian carcinoma were recruited and randomly
assigned to the cisplatin/paclitaxel/ifosfamide (CIP) or cisplatin/
paclitaxel/epirubicin (CEP) treatment arm. Inclusion criteria were
International Federation of Gynecologic Oncology stage II–IV,
Eastern Cooperative Oncology Group performance status 0–2, no
prior chemotherapy or radiotherapy, adequate haematologic,
hepatic and renal function defined as absolute neutrophil count
41.5 10
9 cells per litre, platelet count at least 100 10
9 cells per
litre, serum creatinine and total bilirubin not more than 1.25 times
the upper normal limit.
Exclusion criteria included mixed mesodermal tumours, border-
line tumours, concurrent malignancies within the previous 5 years
(excluding basal cell carcinoma), pregnancy, lactation, peripheral
neuropathy of grade 2 or higher, congestive heart failure and
cardiac arrhythmias.
Patients were randomised within 4 weeks of surgery. The study
had ethics committee approval from the two participating centres
(San Gerardo Hospital, Monza, Italy and European Institute of
Oncology, Milan, Italy), and all the patients gave written informed
consent.
Treatment plan
Six cycles of chemotherapy were planned with 3-week intervals
between them, the first cycle starting within 2 weeks of
randomisation.
In CEP, drug doses were epirubicin 80mgm
 2, paclitaxel
175mgm
 2 and cisplatin 75mgm
 2. Epirubicin was administered
before paclitaxel (Venturini et al, 2000). In CIP, paclitaxel and
cisplatin doses were the same as for CEP; ifosfamide was given at
5gm
 2 with the chemoprotectant MESNA.
Cycles were repeated if no progressive disease or prohibitive
toxicity occurred. Treatment was delayed for up to 2 weeks if the
neutrophil count was less than 1.5 10
9 per litre and the platelet
count was less than 100 10
9 per litre on day 1 of each cycle.
Dose reductions were allowed in any of the following
circumstances: 1-week cycle delay for two cycles in succession or
2-week cycle delay because of prolonged bone marrow depression;
febrile neutropaenia or thrombocytopaenic bleeding; any drug-
related side effect requiring hospitalisation with i.v. antibiotics or
platelet transfusion. Dose-reduction levels were epirubicin
60mgm
 2 (level 1) and 45mgm
 2 (level 2), ifosfamide 2.5gm
 2
(level 1) and 1.5gm
 2 (level 2), cisplatin 50mgm
 2 (level 2) and
paclitaxel 135mgm
 2 (level 2).
Patients with a partial response after the six cycles of
chemotherapy could receive additional treatment cycles or a
second chemotherapeutic regimen, at the investigator’s discretion.
Clinical assessment
CA125 levels were measured before each cycle. Response was
assessed with a CT scan after the third and the last cycles. The
CA125 response was classified according to the method of Rustin
et al (1996). Clinical response was assessed using WHO criteria
(Miller et al, 1981). Adverse events and toxicity were graded using
the National Cancer Institute Common Toxicity Criteria version 2.0
(National Cancer Institute). Second-look surgery was permitted.
Follow-up for each patient consisted of a physical examination
every 3 months for the first 3 years after chemotherapy, every 6
months in the next 2 years and one visit every year thereafter.
CA125 was measured before each visit. Computed tomography was
repeated yearly for 5 years, if there was any suspicion of relapse or
progressive disease.
Statistical analysis
This was a phase II, multicentre, randomised clinical trial. Sample
size was based on the assumption of a pathologic complete
response (pCR) rate of 20% with standard treatment, and was
planned to exclude a pCR o15% with a¼0.05, and to recognise a
pCR¼30% with a power¼0.85. According to these criteria, 51
evaluable patients per arm (60 randomised) should have been
entered. Data of this phase II study have been published (Colombo
et al, 1999), leading to the following conclusions: (1) both regimens
were feasible and (2) pCR rates were higher than those expected
with other standard therapies. Therefore, based on these positive
evidences, it was decided to continue the study to confirm positive
response rates in a larger sample and to obtain long-term survival
data and further confirmatory evidence to move a regimen into a
phase III trial. Sample size was based on the assumption that the
historic median survival is 36 months in patients receiving the
reference platinum and paclitaxel doublet regimen (CP). Given
this assumption and that a 33% improvement in 3-year survival
(hazard ratio¼0.66, which translates into increases from 50 to
63% in 3-year survival) was considered as sufficient evidence to
move a regimen into a phase III trial, each treatment arm was
planned to have about 100 patients (type-I error limited to 0.05
(one-tailed test); power 0.80). For this further analysis, primary
end point was OS, defined as the time from randomisation to death
from any cause. Secondary end points were PFS, defined as the
time from randomisation to the earliest occurrence of progression
or death from any cause and overall response rate. Other
secondary outcome measures aimed to assess safety included
frequency and severity of adverse events. Patients meeting all
inclusion criteria were consecutively randomised by a central data
centre.
This study was noncomparative and was not powered to
demonstrate differences between treatment arms. Although no
formal statistical comparison of the two arms was planned,
survival curves were estimated by the Kaplan–Meier method and
compared using the log-rank test. Additional time-to-event
analyses were done using the Cox proportional hazards model,
adjusting for multiple baseline characteristics. Fisher’s exact test
was done on the response rates and toxicity levels. These tests were
for exploratory purposes only, and all P-values are two-sided;
statistical significance was set at 0.05 and analysis was done using
SAS software version 9.0 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Population
Two hundred and eight patients were randomised between the two
treatment arms (106 to CIP and 102 to CEP) in the two recruiting
centres (San Gerardo Hospital, Monza and European Institute of
Oncology, Milan). One patient allocated to the CEP arm was
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sineligible because of a diagnosis of pancreatic metastatic
carcinoma. One patient allocated to the CIP arm died before
receiving any chemotherapy. Three patients allocated to CIP and
three to CEP received only platinum and paclitaxel. One patient
allocated to the CIP arm refused the chemotherapy. Therefore 199
patients were eligible for safety and efficacy assessment (101 in the
CIP arm and 98 in the CEP arm).
The two treatment arms were well balanced with respect to
baseline characteristics (Table 1).
Toxicity
A total of 1149 cycles of chemotherapy were administered (575
CIP, 574 CEP), and toxicity data were available for 85% of the
cycles; maximum toxicity grades were available for all the patients.
Treatment changes because of toxicity for each drug are shown
in Table 2. In the CIP arm, 38% of patients received the planned
dose of ifosfamide, 46% received a one-level reduction and 16% a
two-level reduction. In the CEP arm, 51% of patients received the
full dose of epirubicin, 46% received a one-level dose reduction
and 3% a two-level dose reduction. One patient in the CEP arm had
to discontinue epirubicin on account of a generalised maculo-
papular rash, and in the CIP arm, ifosfamide was suspended after
the third cycle for a worsening of chronic hepatitis.
Haematological toxicity is summarised in Table 3. Nonhaema-
tological toxicity is shown in Table 4.
Allergic reactions were all to paclitaxel and occurred in 23
patients in all; 21 consisted only of short-lasting flushing without
fever (grade 1), while one patient in the CIP arm experienced a
grade 3 (oedema) and one a grade 4 (anaphylaxis) allergic reaction.
Both these patients were able to receive the remaining cycles of
chemotherapy after the adverse event, with a change in
premedication. There were two cases of cardiovascular toxicity
(one had tachycardia and one a cardiac ischaemia that did not
require intervention) in the CIP arm only. The two patients in the
CEP arm who had grade 2 vascular toxicity had superficial
phlebitis, while the only patient with grade 4 toxicity had
pulmonary thromboembolism.
Response rates
Clinical and pathological responses to treatment are summarised
in Table 5. Of the 191 patients with stage III–IV disease who
received at least two cycles of chemotherapy, 172 were assessable
for response. Response was not evaluable in 19 patients (11 in the
CIP arm and 8 in the CEP arm) because they had no evidence of
disease after the first surgery and no positive CA125 levels at the
Table 1 Patients’ main characteristics
CIP (n¼101) CEP (n¼98)
%%
Age (years)
Median 52 52
Range 27 24
73 71
BSA (m
2)
Median 1.6 1.6
Range 1.3 1.3
2.4 2.0
PS
08 9 9 2
19 8
22 0
FIGO stage
IIA 0 2
IIB 3 1
IIC 1 1
IIIA 1 3
IIIB 6 4
IIIC 76 74
IV 13 15
Histology
Serous 64 70
Mucinous 4 3
Endometrioid 19 10
Clear cells 5 7
Poorly differentiated 8 10
Grade
14 6
22 0 1 4
37 6 8 0
Residual tumour
NED 20 15
o 1cm 14 24
1–2cm 14 11
2–5cm 23 18
5–10cm 11 19
410cm 18 13
Type of surgery
a
13 0 1 7
24 4 5 2
31 9 2 3
47 8
Abbreviations: BSA¼body surface area; CEP¼cisplatin/paclitaxel/epirubicin;
CIP¼cisplatin/paclitaxel/ifosfamide; FIGO¼Federation of Gynecologic Oncology;
NED¼no evidence of disease; PS¼performance status.
a1¼laparotomic
histerectomy, bilateral annesiectomy, omentectomy, appendicectomy, pelvic
linphoadenectomy; 2¼laparotomic histerectomy, bilateral annesiectomy,
omentectomy, appendicectomy; 3¼laparotomic histerectomy, bilateral annesiect-
omy; 4¼biopsies only.
Table 2 Treatment modifications and toxicity management in both arms
CIP (n¼101) CEP (n¼98)
Toxicity % % P
Number of cycles administered 575 574
Number of patients delayed 49 37 0.08
Weeks of treatment delay, total 116 117
Cisplatin reduction 21 22 0.81
Paclitaxel reduction 27 17 0.09
Epirubicin/ifosfamide reduction 62 49 0.07
Abbreviations: CEP¼cisplatin/paclitaxel/epirubicin; CIP¼cisplatin/paclitaxel/ifosfamide.
Table 3 Grade 3–4 haematological toxicity and management in both
arms
CIP (n¼101) CEP (n¼98)
Toxicity % % P
Anaemia 48 27 0.002
Leukopaenia 95 76 0.0001
Neutropaenia 97 95 0.51
Thrombocytopaenia 37 25 0.08
Febrile neutropaenia, grade 3 14 3 0.007
G-CSF 48 22 0.0002
Transfusion 37 22 0.03
Hospitalisation 34 19 0.02
Abbreviations: CEP¼cisplatin/paclitaxel/epirubicin; CIP¼cisplatin/paclitaxel/ifosfamide;
G-CSF¼granulocyte colony-stimulating factors.
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sstart of chemotherapy. Of the 123 patients with suboptimal
debulking (residual tumour (RT) 41cm) after first surgery, 95
underwent second-look laparoscopy after the planned course of
chemotherapy. Thirty-three of the 68 patients with microscopic or
no residual disease after the first surgery underwent the same
procedure; thus pathological response could be evaluated on
128/191 patients (67%). Responses of the remaining 44 patients
(28 with measurable disease and 16 with positive CA125 only) were
evaluated on the basis of clinical, radiological and biochemical
data.
Overall, 38 patients had a clinical complete/partial response,
while 113 had a pathological complete/partial response.
Response rates were 85% (95% CI 77–93%) in the CIP arm and
90% (95% CI 84–96%) in the CEP arm; complete response rates
were 48 and 52%.
Survival analysis
Overall survival was analysed excluding the eight patients with
stage II ovarian cancer. No patient was lost to follow-up.
Therefore, survival data were available for a total of 191 patients
(97 in the CIP arm and 94 in the CEP arm). Median follow-up was
82 months. Median OS was 51 months in the CIP arm and 65
months in the CEP arm (Figure 1A and B). Median OS was 54
months for all patients, and 57 months including the eight patients
with stage II disease. Median OS was only 43 months for patients
who had been suboptimally debulked. Patients with RT 45cm
after first surgery had OS 31 months (33 in the CEP arm and 30
months in the CIP arm). Median PFS was 25 months in the CIP
arm and 23 months in the CEP arm (Figure 2A and B). Overall
survival at the third and the fifth year of the patients on CIP was
59% (95% confidence interval (CI) 48–69%) and 43% (95% CI 33–
53%), and for patients on CEP was 68% (95% CI 58–77%) and 50%
(95% CI 40–60%), respectively. Although both regimens were
active, only CEP regimen would formally merit further study as the
third year OS for this regimen was significantly better than
historical rate (i.e. the lower CI of third year OS was higher than
50%).
DISCUSSION
One of the secondary objectives of this study was to compare the
toxicity of the two experimental regimens and assess their
feasibility, because one of the main risks of adding a third drug
to standard chemotherapy is a predictable increase in adverse
events.
Overall, both the combinations used in this phase II clinical trial
showed good feasibility and acceptable tolerability and toxicity,
especially CEP, using the two drugs under investigation at
Table 5 Response to treatment for patients with stage III–IV disease
CIP (n¼97) CEP (n¼94)
Response No. (%) No. (%)
Complete response 41 (48) 45 (52)
Clinical 12 (14) 14 (16)
Pathological 29 (34) 31 (36)
Partial response 32 (37) 33 (38)
Clinical 4 (5) 8 (9)
Pathological 28 (33) 25 (29)
Stable disease 10 (12) 7 (8)
Clinical 3 (3) 1 (1)
Pathological 7 (8) 6 (7)
Progressive disease 3 (3) 1 (1)
Clinical 2 (2) 0
Pathological 1 (1) 1 (1)
Inevaluable
a 11 8
Abbreviations: CEP¼cisplatin/paclitaxel/epirubicin; CIP¼cisplatin/paclitaxel/ifosfamide.
aResponse was not evaluable in patients without evidence of disease after the
first surgery and negative CA125.
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Figure 1 (A) Overall survival for the CEP regimen. (B) Overall survival
for the CIP regimen.
Table 4 Nonhaematological toxicity in both treatment arms
CIP (n¼101) CEP (n¼98)
Grade 1–2 Grade 3–4 Grade 1–2 Grade 3–4
Toxicity % % % %
Allergy 13 2 8 0
Cardiac 1 1 0 0
Vascular 0 1 2 0
Artromyalgia 37 5 39 5
Nausea 78 21 76 24
Vomiting 73 24 80 17
Mucositis 43 3 53 2
Fever
a 38 2 19 0
Infection 16 2 15 2
Neurotoxicity 59 3 69 0
Alopaecia 0 98 0 98
Abbreviations: CEP¼cisplatin/paclitaxel/epirubicin; CIP¼cisplatin/paclitaxel/ifosfamide.
aStatistically significant difference between the two treatment regimens (Po0.01).
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srelatively high doses. As expected from published toxicity data, the
CIP arm was more toxic than the CEP arm. More than 60% of
patients who received CIP did not tolerate the starting dose of
5gm
 2 ifosfamide and required at least one dose-level reduction.
However, even in the CEP arm, almost half the patients could not
complete the six courses of chemotherapy with the planned doses
of the three drugs.
In our opinion, the main limitation to CIP polychemotherapy at
the doses presented in this trial is that its toxicity seems less
manageable than with CEP, as indicated by the higher frequency of
leucopaenia (P¼0.0001), anaemia (P¼0.002), need for granulo-
cyte colony-stimulating factor (G-CSF) (P¼0.0002) and transfu-
sion (P¼0.03) and, above all, the higher incidence of febrile
neutropaenia, considered as a potentially life-threatening event.
The subsequent need for hospitalisation, besides worsening
patients’ quality of life, raises the costs of therapy.
Toxicity in the CIP arm was greater than reported elsewhere;
however, the phase I dose-escalating study (Papadimitriou et al,
2001) used prophylactic G-CSF and had febrile neutropaenia in
one patient out of eight treated at doses comparable with ours, and
the phase II trial (Kosmas et al, 2001) reported less frequent high-
grade haematological toxicity but used only 1.5gm
 2 ifosfamide,
which is 70% lower than the dose we used. Overall, the results of
this study indicate low feasibility of the CIP regimen with a starting
dose of 5gm
 2 ifosfamide, at least without prophylactic G-CSF.
On the other hand, most patients recovered from the toxicity
induced by CEP with a dose reduction and a week’s delay of
therapy. The heavier toxicity of CIP would only be justified by
greater efficacy than CEP or the standard chemotherapy. However,
the two regimens showed similar results in terms of response rates.
As expected, response rates obtained in this trial are similar to
those reported elsewhere.
Although no formal comparison of the two regimens was done
in terms of OS, only the CEP regimen showed a significant
improvement over historical therapy in the 3-year survival rate,
which was the formal target outcome for our experimental design.
However, it was the long-term survival in both study arms, which
was noteworthy on account of the absence of patients lost to
follow-up and the unusually long median follow-up (82 months),
that merits comment. Median OS for all patients with stage III–IV
epithelial ovarian cancer treated in the two arms was 54 months,
and 62 months in the CEP arm. This is particularly interesting
because 65% of patients in our study had an RT after first surgery
41cm. Median OS for patients with an RT o1cm has not yet
been reached in either group, while it was 44 months for patients
with an RT 41cm.
Even if this study had no control arm with the standard
carboplatin–paclitaxel chemotherapy, making it impossible to
compare the OS obtained with our experimental regimens, we did
try to compare the results with some of the major randomised
clinical trials published in the last 20 years (Table 6).
Since the introduction of platinum compounds in first-line
chemotherapy, PFS has not improved much over the years,
but OS has risen from about 20 months in the 1980s (Conte et al,
1986; Alberts et al, 1992; Rothenberg et al, 1992; Swenerton et al,
1992; Alberts et al, 1996) to 30 months in the 1990s (McGuire
et al, 1996; ICON Collaborators, 1998; Muggia et al, 2000)
and 40 months in the last few years (Markman et al, 2001;
ICON Collaborators, 2002; Du Bois et al, 2003; Armstrong et al,
2006). In our series, PFS was slightly better than is commonly
reported and considering the composition of our population,
OS of 54 months is remarkable. Comparable results are reported
only in trials that enrolled only patients with minimal or no
residual disease after the first surgery (Alberts et al, 1996;
Markman et al, 2001; ICON Collaborators, 2002; Armstrong
et al, 2006), and in other studies that considered the subgroup of
patients with this positive prognostic factor (du Bois et al, 2006;
Pfisterer et al, 2006).
Interestingly, a recently published study on the role of
aggressive cytoreductive surgery in the treatment of advanced
ovarian cancer reports a 5-year survival rate of 46% for patients
who underwent radical surgery, similar to the present result
(Eisenkop et al, 2003; Aletti et al, 2006).
However, some recently published randomised clinical trial
(Bookman et al, 2006; du Bois et al, 2006; Pfisterer et al, 2006)
failed to demonstrate an advantage for the triplets in the treatment
of ovarian cancer patients compared to the standard doublet,
showing an increased toxicity associated with the experimental
treatment arms. Therefore, considering that our populations had
no favourable clinical or biological prognostic factors, one of the
reasons for better oncological outcome in our study might be the
diagnostic and therapeutic procedures that followed first-line
chemotherapy. Second-look laparoscopy was done in 67% of
patients, and patients with persistent disease received a second
chemotherapy course. After second-line chemotherapy laparo-
scopy was repeated, and the treatment was continued until
pathological evidence of complete response. Of the 120 patients
alive after 3 years, only 23% had not received any further
chemotherapy after the first-line, whereas 42% received three or
more different regimens; this proportion reaches 53% among
patients with suboptimal debulking.
This last observation suggests that the long PFS and OS of our
patients might have been attributed to the chronicity of the
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Figure 2 (A) Progression-free survival for the CEP regimen. (B)P r o g r e s s i o n -
free survival for the CIP regimen
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spostsurgical therapies, despite the fact that consolidation therapy of
ovarian cancer has not been proven to increase survival. In addition,
the impact of chronic chemotherapies on the quality of life of patients
with ovarian cancer needs to be performed in future studies.
Another factor that might have influenced our results is the
cumulative dose of cisplatin. Following the trial protocol, we tried
to give all patients the full platinum dose, reducing the two
experimental drugs epirubicin and ifosfamide by one-dose levels in
case of toxicity without recovery before reducing cisplatin and
paclitaxel.
In conclusion, both CIP and CEP showed good efficacy during
long-term follow-up, but toxicity was greater than indicated by
historical data with the standard carboplatin/paclitaxel chemotherapy.
This observation adds to the evidence that adding a third drug to
the standard chemotherapy does increase the toxicity but gives no
clear advantage in efficacy. By integrating information such
as OS and toxicity, the combination of cisplatin, paclitaxel and
epirubicin we used should be chosen over CIP regime. Cisplatin/
paclitaxel/epirubicin arm gave a very high 5-year survival rate, but
in the absence of a comparison with current standard treatment, it
cannot be recommended as first-line chemotherapy for advanced
ovarian cancer.
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